Targeted Protein Degradation Therapy Key Players

Top Companies in the Targeted Protein Degradation Market & Their Offerings

What are the Recent Developments in the Targeted Protein Degradation Market?

• In April 2024, Novartis strengthened its targeted protein degradation portfolio by acquiring VVD-101, a late-stage protein degrader candidate from Vividion Therapeutics for prostate cancer treatment. The therapy is designed to target the androgen receptor associated with cancer progression, supporting Novartis’ focus on advancing innovative oncology therapies and expanding its clinical development pipeline.
• In March 2024, C4 Therapeutics entered into a strategic research collaboration with Merck KGaA, Darmstadt, Germany, to advance targeted protein degradation therapies for oncology applications. The partnership focuses on utilizing C4 Therapeutics’ Degronimid platform to develop innovative small-molecule degraders aimed at critical cancer-related proteins, strengthening research and drug discovery efforts in the market.

Supply Chain Analysis

Clinical Trials

• Targeted Protein Degradation (TPD) is emerging as a fast-growing therapeutic area, with more than 40 drug candidates currently under clinical development, primarily for cancer treatment applications such as breast cancer, prostate cancer, and blood-related malignancies. The market is gaining strong attention due to increasing advancements in PROTAC technology and rising investments in precision medicine.
•  Key players: Arvinas, C4 Therapeutics, Kymera Therapeutics, and Nurix Therapeutics.

Distribution to Hospitals, Pharmacies

• Targeted protein degradation therapeutics are gradually moving from clinical research stages toward commercial availability, increasing their presence across hospital and retail pharmacy channels. Growing demand for advanced precision therapies and expanding approvals for innovative degradation-based drugs are supporting market expansion. 
• Key players: Bristol Myers Squibb, Pfizer, Amgen, and Monte Rosa Therapeutics

Patient Support and Services 

• Patient support and service activities in the targeted protein degradation market are mainly centered on clinical development, research assistance, and therapy accessibility for cancer, neurological, and other difficult-to-treat diseases. As TPD therapies continue to advance, companies are increasingly focusing on improving patient access, clinical trial support, and treatment development processes to accelerate commercialization. 
• Key players: Boehringer Ingelheim, Genentech, Foghorn Therapeutics, and Captor Therapeutics.

Market Growth

The global targeted protein degradation therapy market size was estimated at USD 3.2 billion in 2025 and is predicted to increase from USD 3.94 billion in 2026 to approximately USD 25.36 billion by 2035, expanding at a CAGR of 23% from 2026 to 2035.